Journals / Çocuk Dergisi / 2019 / Cilt: 19 - Sayı: 3

Group B Meningococcal Infections and Vaccination

Grup B Meningokok Enfeksiyonları ve Aşılama

Pages
116–123
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Protection against serogroup B, which appears to be in the forefront, has been sought and recently, serogroup B vaccine 4CMenB has been developed by reverse vaccination method.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Meningococcal infections leading to endemics and epidemics all over the world can lead to mortality resulting in hours.
📊
Key Findings & Data:According to the surveillance data, serogroups A, B, C, W135 and Y were the most common causes of epidemics.
💡
Conclusion & Impact:Protection against serogroup B, which appears to be in the forefront, has been sought and recently, serogroup B vaccine 4CMenB has been developed by reverse vaccination method.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Meningokok B · invazif meningokokal hastalık · çocukluk çağı

Abstract

Meningococcal infections leading to endemics and epidemics all over the world can lead to mortality resulting in hours. Factors such as geographical characteristics, host factors, serogroup of microorganism affect the course. According to the surveillance data, serogroups A, B, C, W135 and Y were the most common causes of epidemics. With the new meningococcal vaccines including serogroups A, C, W135 and Y, the incidence of these serogroups decreased significantly all over the world. In our country, meningococcal diseases have been striking after the immunization program has been enriched with the addition of Hib and pneumococcal vaccines. Protection against serogroup B, which appears to be in the forefront, has been sought and recently, serogroup B vaccine 4CMenB has been developed by reverse vaccination method.

Özet

Dünyanın heryerinde endemi ve epidemilere neden olan meningokokal enfeksiyonlar, saatler içerisinde mortalite ile sonuçlanan tablolara yol açabilir. Coğrafi özellikler, konak faktörü, mikroorganimanın serogrubu gibi faktörler seyri etkilemektedir. Edinilen sürveyans verilerine göre epidemilere en sık neden olan serogruplar A, B, C, W135 ve Y olarak belirlenmiştir. Bunun üzerine geliştirilen A, C, W135 ve Y serogruplarını içeren yeni meningokok aşıları ile tüm dünyada bu serogrupların görülme oranı belirgin olarak azalma göstermiştir. Ülkemizde ise bağışıklama programının Hib ve pnömokok aşılarının eklenmesiyle zenginleştirilmesinden sonra meningokokal hastalıklar çarpıcı bir şekilde kendini göstermiştir. Ön planda olduğu görülen serogrup B’ye karşı korunmanın yolları aranmış ve son dönemde ters vaksinoloji yöntemiyle serogrup B aşısı 4CMenB geliştirilmiştir

🔖

Cite This Article

KABA, Ö., SOMER, A. (2019). Group B Meningococcal Infections and Vaccination. Çocuk Dergisi, Cilt: 19 - Sayı: 3, 116–123. https://ajindex.com/articles/149576

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Pace D, Pollard AJ. Meningococcal disease: Clinical presentation and sequele. Vaccine 2012;305:3-9.
  2. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013 Sep 10;11(1):17.
  3. Muttalif AR, Presa JV, Haridy H, Gamil A, Serra LC, Cané A. Incidence and Prevention of Invasive Meningococcal Disease in Global Mass Gathering Events. Infect Dis Ther. 2019 Aug 30.
  4. Vespa Presa J, Abalos MG, Sini de Almeida R, Cane A. Epidemiological burden of meningococcal disease in Latin America: A systematic literature review. Int J Infect Dis. 2019 Aug; 85:37-48.
  5. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010;10(5):317- 28.
  6. Centers for Disease Control and Prevention. Meningococcal home. Meningococcal disease in other countries. (Accessed November 12, 2019, available at
  7. Adams DA, Thomas KR, Jajosky RA, Foster L, Sharp P, Onweh DH, et al. Summary of Notifiable Infectious Diseases and Conditions - United States, 2014. MMWR Morb Mortal Wkly Rep 2016;63:1.
  8. Centers for Disease Control and Prevention. Meningococcal home. Surveillance.Surveillance Data Tables. (Accessed November 12, 2019, available at https://www.cdc.gov/meningococcal/surveillance/ surveillance-data.html#figure02
  9. European Centre for Disease Prevention and Control. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA. Stockholm: ECDC; 2017
  10. Ceyhan M, Yildirim I, Balmer P, Borrow R, Dikici B, Turgut M, et al. A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis. 2008;14:1089-96
  11. Ceyhan M, Ozsurekci Y, Gürler N, Karadag Oncel E, Camcioglu Y, Salman N, et al. Bacterial agents causing meningitis during 2013-2014 in Turkey:A multi-center hospital-based prospective surveillance study. Hum Vaccin Immunother 2016 Nov;12(11):2940-5.
  12. Marshall GS, Dempsey AF, Srivastava A, Isturiz RE. US College Students Are at Increased